These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31993737)

  • 1. Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).
    Okada KI; Kawai M; Hirono S; Kojima F; Tanioka K; Terada M; Miyazawa M; Kitahata Y; Iwahashi Y; Ueno M; Hayami S; Murata SI; Shimokawa T; Yamaue H
    Langenbecks Arch Surg; 2020 Feb; 405(1):23-33. PubMed ID: 31993737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of apparent diffusion coefficient prior to neoadjuvant therapy is a predictor of histologic response in patients with borderline resectable pancreatic carcinoma.
    Okada KI; Hirono S; Kawai M; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Hayami S; Kojima F; Yamaue H
    J Hepatobiliary Pancreat Sci; 2017 Mar; 24(3):161-168. PubMed ID: 28064462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
    Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
    Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a phase II trial.
    Uemura K; Kondo N; Sudo T; Sumiyoshi T; Shintakuya R; Okada K; Baba K; Harada T; Murakami Y; Takahashi S
    J Hepatobiliary Pancreat Sci; 2024 May; 31(5):351-362. PubMed ID: 38156372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
    Ielpo B; Duran H; Diaz E; Fabra I; Caruso R; Ferri V; Malavé L; Hidalgo M; Alvarez R; Plaza C; Quijano Y; Vicente E
    Eur J Surg Oncol; 2016 Sep; 42(9):1394-400. PubMed ID: 26899943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery.
    Miyasaka Y; Ohtsuka T; Kimura R; Matsuda R; Mori Y; Nakata K; Kakihara D; Fujimori N; Ohno T; Oda Y; Nakamura M
    Ann Surg Oncol; 2019 May; 26(5):1528-1534. PubMed ID: 30868514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer.
    Okada KI; Hirono S; Kawai M; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Hayami S; Yamaue H
    Anticancer Res; 2017 Feb; 37(2):853-858. PubMed ID: 28179342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A Case of Pathological Complete Response Following Neoadjuvant Chemotherapy with Gemcitabine plus Nab-Paclitaxel in Borderline Resectable Pancreatic Cancer].
    Ohno N; Ishida M; Ohnishi K; Sawai K; Tabata S; Deguchi M; Kitajima T; Kaizaki Y
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1735-1738. PubMed ID: 29394759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial).
    Okada KI; Shimokawa T; Hirono S; Kawai M; Sho M; Satoi S; Matsumoto I; Eguchi H; Murakami Y; Yamada S; Doi M; Yamaue H;
    Oncology; 2017; 93(5):343-346. PubMed ID: 28719890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
    Masui T; Doi R; Kawaguchi Y; Sato A; Nakano K; Ito T; Anazawa T; Takaori K; Uemoto S
    Surg Today; 2016 Nov; 46(11):1282-9. PubMed ID: 26860274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated 68 Ga-FAPI-04 PET/MR in Pancreatic Cancer : Prediction of Tumor Response and Tumor Resectability After Neoadjuvant Therapy.
    Zhang Z; Guo S; Cheng C; Cao K; Jiang H; Jin G; Zuo C
    Clin Nucl Med; 2024 Aug; 49(8):715-721. PubMed ID: 38914015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
    Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
    Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients.
    Huang X; Knoble JL; Zeng M; Aguila FN; Patel T; Chambers LW; Hu H; Liu H
    PLoS One; 2016; 11(12):e0166606. PubMed ID: 27935952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.